Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures

L. N. Binn, W. H. Bancroft, S. M. Lemon, R. H. Marchwicki, James LeDuc, C. J. Trahan, E. C. Staley, C. M. Keenan

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Studies were conducted on the preparation, inactivation, safety, and immunogenicity of a prototype hepatitis A virus vaccine prepared from infected cell cultures. BS-C-1 cells maintained in medium 199 without serum were infected with the HM175 strain of hepatitis A virus and harvested after 21-28 days. The harvested virus preparation contained 6.8-7.4 (log10) cell culture infectious doses/ml. After exposure to 1:4,000 formalin at 35 C, the infectivity titer decreased 106-fold in 30 hr at an exponential rate, although virus was detected in 5.0-ml vaccine samples for up to three days. Three separate vaccine lots elicited antibody in all the guinea pigs given three doses. Owl monkeys given three doses of vaccine did not have any evidence of HAV infection but developed antibodies identifiable by radioimmunoassay and serum neutralization tests. After either oral or intravenous challenge with at least 106 monkey infectious doses of a virulent field strain of hepatitis A virus, none of the vaccinated monkeys shed virus in their feces or had elevated serum levels of alanine aminotransferase. The findings suggest that an effective inactivated whole virus hepatitis A vaccine can be prepared from cell culture.

Original languageEnglish (US)
Pages (from-to)749-756
Number of pages8
JournalJournal of Infectious Diseases
Volume153
Issue number4
StatePublished - 1986
Externally publishedYes

Fingerprint

Hepatitis A Vaccines
Hepatitis A virus
Inactivated Vaccines
Cell Culture Techniques
Viruses
Vaccines
Haplorhini
Serum
Aotidae
Neutralization Tests
Antibodies
Alanine Transaminase
Feces
Formaldehyde
Radioimmunoassay
Guinea Pigs
Safety
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Binn, L. N., Bancroft, W. H., Lemon, S. M., Marchwicki, R. H., LeDuc, J., Trahan, C. J., ... Keenan, C. M. (1986). Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. Journal of Infectious Diseases, 153(4), 749-756.

Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. / Binn, L. N.; Bancroft, W. H.; Lemon, S. M.; Marchwicki, R. H.; LeDuc, James; Trahan, C. J.; Staley, E. C.; Keenan, C. M.

In: Journal of Infectious Diseases, Vol. 153, No. 4, 1986, p. 749-756.

Research output: Contribution to journalArticle

Binn, LN, Bancroft, WH, Lemon, SM, Marchwicki, RH, LeDuc, J, Trahan, CJ, Staley, EC & Keenan, CM 1986, 'Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures', Journal of Infectious Diseases, vol. 153, no. 4, pp. 749-756.
Binn LN, Bancroft WH, Lemon SM, Marchwicki RH, LeDuc J, Trahan CJ et al. Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. Journal of Infectious Diseases. 1986;153(4):749-756.
Binn, L. N. ; Bancroft, W. H. ; Lemon, S. M. ; Marchwicki, R. H. ; LeDuc, James ; Trahan, C. J. ; Staley, E. C. ; Keenan, C. M. / Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. In: Journal of Infectious Diseases. 1986 ; Vol. 153, No. 4. pp. 749-756.
@article{e2abfa3ab2604d08a2b8ec8b8ca4d425,
title = "Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures",
abstract = "Studies were conducted on the preparation, inactivation, safety, and immunogenicity of a prototype hepatitis A virus vaccine prepared from infected cell cultures. BS-C-1 cells maintained in medium 199 without serum were infected with the HM175 strain of hepatitis A virus and harvested after 21-28 days. The harvested virus preparation contained 6.8-7.4 (log10) cell culture infectious doses/ml. After exposure to 1:4,000 formalin at 35 C, the infectivity titer decreased 106-fold in 30 hr at an exponential rate, although virus was detected in 5.0-ml vaccine samples for up to three days. Three separate vaccine lots elicited antibody in all the guinea pigs given three doses. Owl monkeys given three doses of vaccine did not have any evidence of HAV infection but developed antibodies identifiable by radioimmunoassay and serum neutralization tests. After either oral or intravenous challenge with at least 106 monkey infectious doses of a virulent field strain of hepatitis A virus, none of the vaccinated monkeys shed virus in their feces or had elevated serum levels of alanine aminotransferase. The findings suggest that an effective inactivated whole virus hepatitis A vaccine can be prepared from cell culture.",
author = "Binn, {L. N.} and Bancroft, {W. H.} and Lemon, {S. M.} and Marchwicki, {R. H.} and James LeDuc and Trahan, {C. J.} and Staley, {E. C.} and Keenan, {C. M.}",
year = "1986",
language = "English (US)",
volume = "153",
pages = "749--756",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures

AU - Binn, L. N.

AU - Bancroft, W. H.

AU - Lemon, S. M.

AU - Marchwicki, R. H.

AU - LeDuc, James

AU - Trahan, C. J.

AU - Staley, E. C.

AU - Keenan, C. M.

PY - 1986

Y1 - 1986

N2 - Studies were conducted on the preparation, inactivation, safety, and immunogenicity of a prototype hepatitis A virus vaccine prepared from infected cell cultures. BS-C-1 cells maintained in medium 199 without serum were infected with the HM175 strain of hepatitis A virus and harvested after 21-28 days. The harvested virus preparation contained 6.8-7.4 (log10) cell culture infectious doses/ml. After exposure to 1:4,000 formalin at 35 C, the infectivity titer decreased 106-fold in 30 hr at an exponential rate, although virus was detected in 5.0-ml vaccine samples for up to three days. Three separate vaccine lots elicited antibody in all the guinea pigs given three doses. Owl monkeys given three doses of vaccine did not have any evidence of HAV infection but developed antibodies identifiable by radioimmunoassay and serum neutralization tests. After either oral or intravenous challenge with at least 106 monkey infectious doses of a virulent field strain of hepatitis A virus, none of the vaccinated monkeys shed virus in their feces or had elevated serum levels of alanine aminotransferase. The findings suggest that an effective inactivated whole virus hepatitis A vaccine can be prepared from cell culture.

AB - Studies were conducted on the preparation, inactivation, safety, and immunogenicity of a prototype hepatitis A virus vaccine prepared from infected cell cultures. BS-C-1 cells maintained in medium 199 without serum were infected with the HM175 strain of hepatitis A virus and harvested after 21-28 days. The harvested virus preparation contained 6.8-7.4 (log10) cell culture infectious doses/ml. After exposure to 1:4,000 formalin at 35 C, the infectivity titer decreased 106-fold in 30 hr at an exponential rate, although virus was detected in 5.0-ml vaccine samples for up to three days. Three separate vaccine lots elicited antibody in all the guinea pigs given three doses. Owl monkeys given three doses of vaccine did not have any evidence of HAV infection but developed antibodies identifiable by radioimmunoassay and serum neutralization tests. After either oral or intravenous challenge with at least 106 monkey infectious doses of a virulent field strain of hepatitis A virus, none of the vaccinated monkeys shed virus in their feces or had elevated serum levels of alanine aminotransferase. The findings suggest that an effective inactivated whole virus hepatitis A vaccine can be prepared from cell culture.

UR - http://www.scopus.com/inward/record.url?scp=0022636904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022636904&partnerID=8YFLogxK

M3 - Article

VL - 153

SP - 749

EP - 756

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -